Global BRAF Kinase Inhibitor Market Overview
The BRAF kinase inhibitor market marketaccounted for USD 879.3 Million in 2020 and is estimated to be USD 2007.5 Million by 2030 and is anticipated to register a CAGR of 8.7%.
BRAF is a kinase enzyme that helps to control abnormal cell growth and signaling. Vemurafenib is an inhibitor of BRAF enzyme which treat V600E mutated BRAF inhibition. These drugs works only for melanoma patients. Melanoma cells without these mutations are not inhibited by vermurafenib and these drugs are paradoxically stimulates the normal BRAF. Most common side effects seen by the patients are arthralgia, skin rashes and photosensitivity. Furthermore, trail of combination Vemurafenib and ipilimumab was stopped in April 2013 because of signs of liver toxicity. Another drug named Dabrafenib is used for treatment of cancer associated with mutated version of gene BRAF which play a role in the regulation of cell growth. Third drug is Encorafenib used for the treatment of certain melanomas which is a small molecule BRAF inhibitor that targets key enzymes in MAPK signaling pathway.
Global BRAF Kinase Inhibitor Market Drivers & Restraints
High prevalence of non-small cell lung cancer
According to American Cancer Society, about 96,480 new patients with melanomas were diagnosed in U.S. by the end of 2019. Hence increasing number of cancer and melanoma patients drives the market of BRAF Kinase inhibitor.
Large number of clinical trials
Large number of clinical trial drugs are in pipeline and rise in commercialization by various companies are the growing factor for the BRAF kinase inhibitor market. Research and development activities are increasing by key players which also boost the market.
However, high cost for cancer treatment and availability of alternative treatment might hamper growth of the global market to a certain extent.
Global BRAF Kinase Inhibitor Market Segmentations & Regional Insights
The global BRAF kinase inhibitor market is segmented based on drug, indication, distribution channel and region.
By Drug, the Global BRAF Kinase Inhibitor market is segmented into Vemurafenib, Dabrafenib and Encorafenib. By Indication, the market is segmented in Metastatic Melanoma, Metastatic Lung Cancer and Others. By Distribution Channel, the Global BRAF Kinase Inhibitor market is segmented into Hospital pharmacies, online pharmacies and others. By region, the Global BRAF Kinase Inhibitor market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Regional Insights:
On region the global BRAF kinase inhibitor market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America holds the dominant position in the market of BRAF kinase inhibitor due to increasing approval of product by regularly authorities. Further, Europe is expected to gain momentum over forecast period due to launching new product in the market of BRAF kinase inhibitor. For instance, In Sept 2018, Pierre Fabre announced that they got marketing authorization for combination of BRAFTOVI and MEKTOVI from European Commission (EC).
Report Scope:
|
Attribute |
Details |
|
Base year for estimation |
2020 |
|
Forecast period |
2020 – 2029 |
|
Market representation |
Revenue in USD Million & CAGR from 2020 – 2029 |
|
Market Segmentation |
By Drug- Vemurafenib, Dabrafenib and Encorafenib. By Indication– Metastatic melanoma, Metastatic lung cancer and Others. By Distribution Channel– Hospital pharmacies, online pharmacies and others |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the global BRAF kinase inhibitor market report based on the drug, indication, distribution channel and region.
Global Covid-19 Sample Collection Kits Market, By Region:
- North America
- Rest of Middle East & Africa
- Middle East & Africa
-
- GCC
- Israel
- South Africa
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
-
- U.S.
- Canada
Global BRAF Kinase Inhibitor Market Competitive Landscape & Key Players
The key players operating in the global BRAF kinase inhibitor market includes include F. Hoffmann-La Roche Ltd., and Novartis AG. Companies are continuously rising the production and supply of drugs to drive the market.
Global BRAF Kinase Inhibitor Market Company Profile
- F. Hoffmann-La Roche Ltd.
- Novartis AG.
Global BRAF Kinase Inhibitor Market Highlights
FAQs
The Global BRAF Kinase Inhibitor market is segmented based on the drug, indication, distribution channel and region.
Increasing incidence of cancers is the major growth driver of global BRAF kinase inhibitor market. Many key players are coming with new drugs and new technologies like topical sildenafil, nicotine patches, and topical allopurinol to overcome this syndrome.
The key players operating in the Global BRAF Kinase Inhibitor market include F. Hoffmann-La Roche Ltd., and Novartis AG.